Combination of IRS / STAT3 dual modifiers and anti-cancer agents to treat cancer

摘要

PROBLEM TO BE SOLVED: To provide a pharmaceutical composition for treating a tumor which has developed resistance to an epidermal growth factor receptor (EGFR) inhibitor and / or an EGFR antibody. An EGFR inhibitor selected from the group consisting of AZD9291, afatinib, neratinib, dacomitinib, posiotinib, CO-1686, HM61713 and AP26113, and / or cetuximab, together with a compound represented by the following formula or a salt thereof. Provided are a pharmaceutical composition containing an EGFR antibody selected from the group consisting of panitumumab and necitumumab. [Selection diagram] None